Seizure: European Journal of Epilepsy
Volume 19, Issue 5 , Pages 296-299 , June 2010

Levetiracetam in submaximal subcutaneous pentylentetrazol-induced seizures in rats

  • Giangennaro Coppola

      Affiliations

    • Clinic of Child Neuropsychiatry, Second University of Naples, Italy
    • Corresponding Author InformationCorresponding author at: Clinic of Child and Adolescent Neuropsychiatry, Department of Psychiatry, Second University of Naples, Via Pansini 5, Naples, Italy. Tel.: +39 081 5666695; fax: +39 081 5666694.
    • ,
  • Salvatore Arcieri

      Affiliations

    • Clinic of Child Neuropsychiatry, Second University of Naples, Italy
    • ,
  • Alfredo D’Aniello

      Affiliations

    • Clinic of Child Neuropsychiatry, Second University of Naples, Italy
    • ,
  • Tullio Messana

      Affiliations

    • Clinic of Child Neuropsychiatry, Second University of Naples, Italy
    • ,
  • Alberto Verrotti

      Affiliations

    • Section of Pediatrics, Department of Pediatrics, University of Chieti, Italy
    • ,
  • Giuseppe Signoriello

      Affiliations

    • Department of Public Health, Second University of Naples, Italy
    • ,
  • Antonio Pascotto

      Affiliations

    • Clinic of Child Neuropsychiatry, Second University of Naples, Italy

Received 17 November 2009 ,Revised 28 February 2010 ,Accepted 18 March 2010.

References 

  1. Coppola G, Mangano S, Tortorella G, Pelliccia A, Fels A, Romano A, et al. Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy. Epilepsy Res. 2004;59:35–42
  2. Di Bonaventura C, Fattouch J, Mari F, Egeo G, Vaudano AE, Prencipe M, et al. Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. Epileptic Disord. 2005;7:231–235
  3. Striano P, Coppola A, Pezzella M, Ciampa C, Specchio N, Ragona F, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology. 2007;17:250–254
  4. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J N166 Levetiracetam Study Group. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology. 2008;70:607–616
  5. Verrotti A, Cerminara C, Domizio S, Mohn A, Franzoni E, Coppola G, et al. Levetiracetam in absence epilepsy. Dev Med Child Neurol. 2008;50:850–853
  6. Gower AJ, Noyer M, Verloes R, Gobert J, Wülfert E. Ucb L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur J Pharmacol. 1992;222:193–203
  7. Gower AJ, Hirsch E, Boehrer A, Noyer M, Marescaux C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res. 1995;22:207–213
  8. Löscher W, Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol. 1993;232:147–158
  9. Löscher W, Hönack D, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazole seizure models. Epilepsy Res. 1991;8:171–189
  10. Woodbury LA, Davenport VD. Design and use of a new electroshock seizure apparatus, and analysis of factors altering seizure threshold and pattern. Arch Int Pharmacodyn Ther. 1952;1:97–107
  11. Swinyard EA. Laboratory evaluation of antiepileptic drugs. Review of laboratory methods. Epilepsia. 1969;10:107–119
  12. Thavendiranathan P, Chow C, Cunnane S, McIntyre Burnham W. The effect of the ‘classic’ ketogenic diet on animal seizure models. Brain Res. 2003;959:206–213
  13. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?. Epilepsia. 2001;42(Suppl 4):13–18
  14. Krall RL, Penry JK, White BG, Kupferberg HJ, Swinyard EA. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia. 1978;19:409–428
  15. Bailleux V, Vallée L, Nuyts JP, Hamoir G, Poupaert JH, Stables JP, et al. Comparative anticonvulsant activity and neurotoxicity of 4-amino-N-(2,6-dimethylphenyl) phthalimide and prototype antiepileptic drugs in mice and rats. Epilepsia. 1995;36:559–565
  16. Doheny HC, Ratnaraj N, Whittington MA, Jefferys JG, Patsalos PN. Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat. Epilepsy Res. 1999;34:161–168
  17. Löscher W, Fiedler M. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. VI. Seasonal influences on maximal electroshock and pentylenetetrazol seizure thresholds. Epilepsy Res. 1996;25:3–10
  18. Klitgaard H, Matagne A, Gobert J, Wülfert E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol. 1998;353:191–206
  19. Likhodii SS, Musa K, Mendonca A, Dell C, Burnham WM, Cunnane SC. Dietary fat, ketosis, and seizure resistance in rats on the ketogenic diet. Epilepsia. 2000;41:1400–1410
  20. Guerrini R. Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs. 2006;8:113–129

PII: S1059-1311(10)00058-0

doi: 10.1016/j.seizure.2010.03.004

Seizure: European Journal of Epilepsy
Volume 19, Issue 5 , Pages 296-299 , June 2010

Article Tools

* Image Usage & Resolution